[1] Ward FJ, Dahal LN, Khanolkar RC, et al. Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy [J]. Immunotherapy, 2014, 6(10): 1073-1084. [2] Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting [J]. Annu Rev Immunol, 2004, 22: 329-360. [3] Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma [J]. N Engl J Med, 2014, 371(23): 2189-2199. [4] Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research [J]. Cancer Immun, 2013, 13: 5. [5] Gerold KD, Zheng P, Rainbow DB, et al. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function [J]. Diabetes, 2011, 60(7): 1955-1963. [6] Corbo C, Orru S, Salvatore F. SRp20: an overview of its role in human diseases [J]. Biochem Biophys Res Commun, 2013, 436(1): 1-5. [7] 刘佩琦,石黎明,贾荣.SRSF3调控口腔癌细胞中SPAG5外显子3的可变剪切的研究[J].口腔医学研究,2016,32(1): 8-11. [8] 郭继华,贾荣.SRp20对口腔癌细胞丙酮酸激酶前体mRNA可变剪切的调控作用[J].武汉大学学报(医学版),2014,35(1): 8-10. [9] Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists [J]. Clin Exp Immunol, 2009, 157(1): 9-19. [10] Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy [J]. J Leukoc Biol, 2013, 94(1): 41-53. [11] Aggarwal S, Sharma SC, N Das S. Dynamics of regulatory T cells (Tregs ) in patients with oral squamous cell carcinoma [J]. J Surg Oncol, 2017, 116(8): 1103-1113. [12] Wang J, Xie T, Wang B, et al. PD-1 blockade prevents the development and progression of carcinogen-induced oral premalignant lesions [J]. Cancer Prev Res (Phila), 2017, 10(12): 684-693. [13] Wu L, Deng WW, Huang CF, et al. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma [J]. Cancer Immunol Immunother, 2017, 66(5): 627-636. [14] Kammerer PW, Toyoshima T, Schoder F, et al. Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma [J]. Oral Oncol, 2010, 46(7): 543-548. [15] Oaks MK, Hallett KM, Penwell RT, et al. A native soluble form of CTLA-4 [J]. Cell Immunol, 2000, 201(2): 144-153. [16] Saverino D, Simone R, Bagnasco M, et al. The soluble CTLA-4 receptor and its role in autoimmune diseases: an update [J]. Auto Immun Highlights, 2010, 1(2): 73-81. [17] Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease [J]. J Immunol, 2000, 164(10): 5015-5018. [18] AlFadhli S. Overexpression and secretion of the soluble CTLA-4 splice variant in various autoimmune diseases and in cases with overlapping autoimmunity [J]. Genet Test Mol Biomarkers, 2013, 17(4): 336-341. [19] Gerold KD, Zheng P, Rainbow DB, et al. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function [J]. Diabetes, 2011, 60(7): 1955-1963. [20] Erfani N, Razmkhah M, Ghaderi A. Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer [J]. Cancer Invest, 2010, 28(8): 828-832. |